Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaEngineROCO:4162 +0.79%82 Return-on-Tangible-Asset is 10.53% as of Mar. 2026, which is 20% above its 10-year median of 8.79. GuruFocus rates ROCO:4162 with a GF Score™ of 82/100 and a GF Value™ of NT$108.18 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, PharmaEngine ranks better than 90.32% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PharmaEngine's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$548.9 Mil. PharmaEngine's average total tangible assets for the quarter that ended in Mar. 2026 was NT$5,211.7 Mil. Therefore, PharmaEngine's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 10.53%.
The historical rank and industry rank for PharmaEngine's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4162'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.14 Med: 8.79 Max: 35.74
Current: 7.83
During the past 13 years, PharmaEngine's highest Return-on-Tangible-Asset was 35.74%. The lowest was 1.14%. And the median was 8.79%.
ROCO:4162's Return-on-Tangible-Asset is ranked better than 90.32% of 1415
companies
in the Biotechnology industry
Industry Median: -35.49
vs ROCO:4162: 7.83
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
PharmaEngine Return-on-Tangible-Asset Related Terms
PharmaEngine Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for PharmaEngine's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4162 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, PharmaEngine's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where PharmaEngine's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 10.53% mean?
PharmaEngine (ROCO:4162) has a Return-on-Tangible-Asset of 10.53% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PharmaEngine and its competitors. This is 20% above median its historical median of 8.79. Over the past decade, PharmaEngine's Return-on-Tangible-Asset has ranged from 1.14 to 35.74. According to the industry distribution chart, PharmaEngine ranks #137 out of 1415 companies in the Biotechnology industry, placing it in the top 9.7%.
Is PharmaEngine's Return-on-Tangible-Asset too high?
PharmaEngine's current Return-on-Tangible-Asset of 10.53% is 20% above median its 10-year median of 8.79. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 35.74. Based on the distribution chart, PharmaEngine ranks #137 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaEngine has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #137 out of 1415 companies for Return-on-Tangible-Asset. This places PharmaEngine in the top 10% of its industry — outperforming the majority of peers. Historically, PharmaEngine's own Return-on-Tangible-Asset has ranged from 1.14 to 35.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PharmaEngine and its competitors. PharmaEngine's current Return-on-Tangible-Asset is 10.53%, which is 20% above median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Possible Value Trap. The stock's GF Value™ is NT$108.18, compared to a current price of NT$63.70 — trading 41.1% below its estimated fair value. The current Return-on-Tangible-Asset is 10.53%, which is 20% above median its 10-year median of 8.79. PharmaEngine's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Return-on-Tangible-Asset is 10.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$63.70 is trading 41.1% below its estimated GF Value™ of NT$108.18.
GuruFocus considers PharmaEngine to be Possible Value Trap.
Key valuation signals for ROCO:4162:
Return-on-Tangible-Asset: 10.53% (20% above median its 10-year median of 8.79)
GF Value™: NT$108.18 vs. price of NT$63.70 (41.1% below fair value)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
82GF Score
Get the complete analysis for ROCO:4162
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
